[January 07, 2015]

RestorGenex to Present at Biotech Showcase 2015

RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company focused on developing products for ophthalmology, oncology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the Biotech Showcase 2015 in San Francisco, CA (News - Alert). Mr. Simes will provide a corporate overview on Tuesday, January 13, at 3:00 pm PST. The presentation will be webcast and available at http://edge.media-server.com/m/p/3bskmh3j and will b archived at www.restorgenex.com.

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com

[ Back To TMCnet.com's Homepage ]